We Are Building Medical Miracles. Why Are We Letting People Die Waiting for Them?

Illustration. The real Johns Hopkins robots are about as wide as a pencil tip and as long as a grain of rice. The question is who they'll be built for.

This is an opinion piece. The facts are sourced at the bottom. The conclusions are mine.

Picture something about the size of a grain of rice.

It has no battery. It has no motor. A magnetic field steers it from outside the body, and it carries medicine to exactly the spot where it's needed: an infection sitting on a human heart.

Now picture what we do today. A patient lies in a hospital bed for weeks, with antibiotics running through an IV, the drug diluted by the time it reaches the heart. If it fails, the doctors raise the dose and risk toxic side effects, or they open the chest.

That's not science fiction. Engineers at Johns Hopkins just built the robots. And if everything works as planned, they say four to six weeks of treatment could shrink to a day or less.

Let Me Be Precise, Because You Deserve That

I believe in precision over panic, and I won't oversell this. These are magnetic millirobots, not AI. So far they've been tested in heart models and pig heart tissue. They haven't been used on a human being. The next step is a beating heart phantom. Endocarditis, the infection they're designed for, hits about 50,000 Americans a year, and nobody should tell those patients a cure is coming next month.

But I'm showing you this story for a reason. It's proof of what's possible when brilliant people point powerful technology at suffering. And it's one of many.

The Miracles Are Already Here

MIT researchers used AI to screen about 6,000 molecules and found one, halicin, that killed multidrug-resistant bacteria through a new mechanism. In 2023, researchers at McMaster and MIT used AI to find abaucin, a compound that targets one of the deadliest hospital superbugs. This past June, a deep learning model found two new antibiotics, MP20 and A1, that wiped out drug-resistant gonorrhea in mice and an organ-on-a-chip model, through mechanisms unlike any antibiotic we use today.

And it isn't only antibiotics. Insilico Medicine's rentosertib, a drug whose target and molecule were both found with generative AI, just entered a Phase III trial for a lung-scarring disease, with the first patient dosed on September 9.

This is what AI is for. This is what I mean when I say technology should answer to human beings.

Then Look at What Happens Next

Here's the part that makes my blood run hot.

In 2018, the FDA approved a new antibiotic called plazomicin, made by a company called Achaogen. It was built to fight some of the most dangerous resistant infections. Its sales that first year were less than a million dollars. Achaogen filed for bankruptcy the following year.

They did everything right. They found the science. They got the approval. And the market punished them for it.

It's not a one-off. The Wall Street Journal reported in 2023 that all six startups that had won FDA approval for new antibiotics since 2017 had gone bankrupt, been bought, or were closing down. About 80 percent of the 300 scientists who worked at those companies had left the field. This March, another one, Iterum, collapsed. A review in Nature puts the arithmetic plainly; developing a new antibiotic costs around $1.2 billion, while sales often top out near $100 million. A cancer drug can bring in billions. An antibiotic that doctors are rightly told to use sparingly might bring in tens of millions.

Read that again. We're not failing to find the cures. We're finding them, and then watching the companies that made them go under, because saving lives responsibly isn't profitable.

Nobody Has to Be a Villain

I'm going to say this the way I believe it. Nobody has to hide the cure in a vault. Nobody has to twirl a mustache. All they have to do is the math, and then decide the math is someone else's problem.

That's how it works. The people with the money look at the spreadsheet and walk away. The people with the power to change the rules look at the headlines and look away. And everyone in between tells themselves it's just how the market works.

But a market isn't a law of nature. We built it. We can rebuild it. Choosing not to is a decision, and it has a body count.

The Body Count

In 2021, an estimated 1.14 million people died directly because of drug-resistant bacterial infections, and 4.71 million deaths were associated with them, according to the largest analysis ever published, in The Lancet. The same research forecasts 39 million deaths from antibiotic resistance between 2025 and 2050. That's three people every minute.

And it isn't only superbugs. A CDC-published study found that people with diabetes, heart disease, or high blood pressure who skipped medication because of cost had 15 to 22 percent higher all-cause mortality than those who didn't. That's an association, not proof of cause, and I want to be honest about that. But behind every percentage is a person who looked at the price, did the math, and decided to go without. And the study notes that many of them had insurance and middle-class incomes.

Imagine a person in that situation. I'm not describing anyone in particular, and I won't pretend to. Imagine someone who raised a family, who worked, who paid in. Now imagine them standing at a pharmacy counter, deciding which pill to cut in half.

Now tell me this is a system working as intended.

What the Stoics Would Say

I talk about Marcus Aurelius because he wrote his Meditations for himself, as a reminder, while running an empire. One of his lines has never left me; what isn't good for the hive isn't good for the bee. He meant that no one thrives apart from the community they belong to. Seneca made the same point when he described all of us as parts of one great body.

Think about what that says about a society that builds a miracle and prices it for the few. A hive that lets half its bees die isn't strong. It's unfinished.

The Stoics also believed in duty. You don't get to watch an injustice and call yourself wise. Marcus also wrote that the obstacle in the path becomes the path. The obstacle here is money, and the path is deciding that it doesn't get the last word.

Who Gets the Miracle?

When those tiny robots reach patients, and I hope they do, here's the question I'll be asking; who gets them first? The patient with the best insurance plan? The one near a major research hospital? Or everyone with a failing heart valve and an infection that won't clear?

I'm not predicting the answer. I'm telling you to demand it before the technology arrives, not after.

What We Can Actually Do

I'm not interested in raw anger that goes nowhere. Anger is fuel. Here's where to aim it.

1. Ask your representatives what they're doing about the antibiotic market failure. Experts call the fix "pull incentives", which means paying for the value of a drug that saves lives, not the number of pills sold. You don't need to know the details. You only need to ask the question.

   
   

2. Call the U.S. Capitol switchboard at (202) 224-3121, ask for your representative and your two senators, and tell them; "I want new antibiotics funded, and I want lifesaving medicine available to everyone, not just those with the best insurance."

   
   

3. Ask the same of any company or university that announces a breakthrough; how will this reach ordinary patients, and what will it cost?

   
   

4. Support the people doing this work. The scientists who left antibiotic research didn't stop caring. They ran out of funding.

   
   

5. Share this. Silence is how systems like this keep running.

   
   

The Last Word

We have never had tools this powerful. AI that can sift thousands of molecules in a weekend. Robots the size of a grain of rice that can steer through a beating heart. And we're about to find out what kind of people we are.

We can use them to build something worthy of the word "civilization". Or we can use them to make the rich richer, and keep leaving everyone else on a waiting list.

Marcus Aurelius asked what a thing is actually for. Not what it claims to be for. What it's actually for. Ask that about every miracle we build.

Stay sharp. Stay loud.

➡️ Related: AI Can Now Map Which Parts of Your Brain Are Aging Faster

➡️ Related: When the Algorithm Says No: The AI That's Deciding Who Gets Treated in America

➡️ Learn more about the Academy Toolkit

➡️ Join the free Tech 4 Grown-Ups community

➡️ Listen to the Podcast

Digital Trends: Tiny robots could shrink weeks of heart infection treatment into a single day (Johns Hopkins study, Advanced Materials Technologies): https://www.digitaltrends.com/cool-tech/tiny-robots-could-shrink-weeks-of-heart-infection-treatment-into-a-single-day/

PBS NewsHour: How AI is helping researchers develop antibiotics to fight drug-resistant infections, May 27, 2026: https://www.pbs.org/newshour/show/how-ai-is-helping-researchers-develop-antibiotics-to-fight-drug-resistant-infections

McMaster University: Scientists use AI to find promising new antibiotic to fight evasive hospital superbug (abaucin), 2023: https://news.mcmaster.ca/artificial-intelligence-new-antibiotic-drug-resistant-pathogen-acinetobacter-baumannii/

Nature: AI tool spots antibiotics that fight drug-resistant gonorrhoea, June 24, 2026: https://www.nature.com/articles/d41586-026-01987-7

Inside Precision Medicine: AI Discovers Two New Antibiotics for Drug-Resistant Gonorrhea (Science Translational Medicine), June 2026: https://www.insideprecisionmedicine.com/topics/informatics/ai-discovers-two-new-antibiotics-for-drug-resistant-gonorrhea/

IntuitionLabs: AI-Discovered Drugs in Clinical Trials 2026 (rentosertib Phase III): https://intuitionlabs.ai/articles/ai-discovered-drugs-clinical-trials-2026

Nature (npj Antimicrobials and Resistance): Current economic and regulatory challenges in developing antibiotics, 2025: https://www.nature.com/articles/s44259-025-00123-1

Wall Street Journal: The World Needs New Antibiotics. The Problem Is, No One Can Make Money Making Them, September 2023: https://www.wsj.com/tech/biotech/antibiotics-drug-development-business-fda-aa5b4f00

The Hill: Iterum's failure highlights crisis in antibiotic development, April 2026: https://thehill.com/opinion/healthcare/5853411-urgent-need-new-antibiotics/

The Lancet: Global burden of bacterial antimicrobial resistance 1990-2021: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext

Wellcome: New forecasts reveal 39 million deaths will be directly attributable to bacterial antimicrobial resistance by 2050: https://wellcome.org/insights/articles/new-forecasts-reveal-39-million-deaths-will-be-directly-attributable-bacterial-antimicrobial

CDC, Preventing Chronic Disease: Cost-Related Nonadherence and Mortality in Patients With Chronic Disease, 2020: https://www.cdc.gov/pcd/issues/2020/20_0244.htm

Michael Routhier is the founder of Tech 4 Grown-Ups, providing honest, unfiltered digital literacy for adults 55+, and host of The Virtuous Machine, exploring the ethics and human cost of AI. Read by tech-curious readers in 200+ countries. Explore more at tech4grownups.com.